---
schema_version: "secwatch.filing_event.v1"
accession: "0001022079-22-000118"
form_type: "8-K"
ticker: "DGX"
cik: "0001022079"
company_name: "QUEST DIAGNOSTICS INC"
filed_at: "2022-07-21T23:59:59+00:00"
generated_at: "2026-06-24T09:47:34.842303+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Quest Diagnostics Q2 rev $2.45B (-3.8% YoY); raises FY22 adj EPS guidance to $9.55-$9.95

## Summary
- Q2 reported diluted EPS $1.96 (down 60.5% YoY); adjusted diluted EPS $2.36 (down 25.8% YoY).
- Base business revenue $2.10B (+2.9% YoY); COVID testing revenue $355M (-30.5% YoY).
- Raises FY22 guidance: net revenues $9.50B-$9.75B, adjusted EPS $9.55-$9.95 (prior $9.00-$9.50).
- CEO-elect Jim Davis cites base business growth and expanded COVID molecular testing share.
- Company supports SALSA legislation to fix PAMA clinical lab fee schedule cuts.

## SEC filing metadata
- accession: 0001022079-22-000118
- form_type: 8-K
- ticker: DGX
- cik: 0001022079
- company_name: QUEST DIAGNOSTICS INC
- filed_at: 2022-07-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/0001022079-22-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1022079/000102207922000118/dgx-20220721.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001022079-22-000118
- JSON: https://secwatch.observer/filing/0001022079-22-000118.json
- Plain text: https://secwatch.observer/filing/0001022079-22-000118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.